Philippe Archinard – CEO, Transgene, France

Phillipe Archinard CEO of Transgene shares insights on the latest technologies being developed by the gene therapy specialist, explains how France’s innovation landscape is improving, and highlights the current opportunities in the market.  
Thanks to their versatility, oncolytic viruses can, therefore, be very potent. Our Invir.IO platform will be revolutionary for tumours that resist currently available treatments.
Become a PharmaBoardroom Member for free to access this content
Join the 20,000+ pharmaceutical professionals who already subscribe to PharmaBoardroom
Register
Already a member? Sign In

Related Interviews

Latest Report